Achieve Life Sciences Inc. Common Shares
(NASDAQ:ACHV)
Description
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
ACHV Overview
None
Sector |
Health Care |
Industry |
Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Previous Close |
$5.3700 |
Previous Close Volume |
51960 |
Latest News
- Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer 09 Dec 2024 08:30:08
- Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA 03 Dec 2024 08:30:09
- Achieve Life Sciences Announces Participation at Upcoming Investor Conferences 14 Nov 2024 08:30:09
- Achieve Life Sciences Reports Financial Results for Third Quarter 2024 and Provides Corporate Update 07 Nov 2024 16:15:04
- Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 7, 2024 24 Oct 2024 08:00:09
- Achieve Life Sciences President and CMO, Dr. Cindy Jacobs, Speaks at FDA and NIH Smoking Cessation Public Meeting 23 Oct 2024 08:15:08
- Achieve Life Sciences Promotes Jaime Xinos to Chief Commercial Officer to Advance Commercial Readiness of Cytisinicline 16 Oct 2024 08:15:09
- Achieve Life Sciences Announces Completion of Enrollment in ORCA-OL Clinical Trial & Successful Outcome of the First Data Safety Monitoring Committee Meeting 10 Oct 2024 08:15:08
- Achieve Life Sciences Strengthens Leadership with Appointment of Dr. Mark Rubinstein, Nicotine Dependence Expert, as New Head of Medical Affairs 01 Oct 2024 09:00:09
- Achieve Life Sciences Announces Changes in Executive Leadership and Board of Directors 26 Aug 2024 16:30:08
- Achieve Life Sciences Reports Financial Results for Second Quarter 2024 and Provides Corporate Update 13 Aug 2024 16:15:08
- Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence 31 Jul 2024 08:15:08
- Achieve Life Sciences Announces $20M Loan Refinancing with Silicon Valley Bank 29 Jul 2024 08:00:09
- Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024 25 Jul 2024 08:00:08
- Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024 09 Jul 2024 08:00:09
- Achieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes 01 Jul 2024 08:00:09
- Achieve Life Sciences Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes 29 May 2024 08:15:05
- Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting 17 May 2024 08:15:09
- Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update 09 May 2024 16:15:09
- Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine 06 May 2024 11:30:09
- Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024 25 Apr 2024 08:00:10
- Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference 11 Apr 2024 08:00:10
- Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update 28 Mar 2024 16:15:08
- Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting 20 Mar 2024 08:00:10
- Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024 14 Mar 2024 08:00:10
- Achieve Life Sciences Announces Participation at Upcoming Investor Conferences 06 Mar 2024 08:00:09
- Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission 29 Feb 2024 08:15:10
- Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement 29 Feb 2024 08:00:09